Genetic Mapping of a Highly Variable Norovirus GII.4 Blockade Epitope: Potential Role in Escape from Human Herd Immunity

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2011 Nov 18

PMID 22090110

Citations 93

Authors

Kari Debbink

Eric F Donaldson

Lisa C Lindesmith

Ralph S Baric

Affiliations

Soon will be listed here.

Abstract

Noroviruses account for 96% of viral gastroenteritis cases worldwide, with GII.4 strains responsible >80% of norovirus outbreaks. Histo-blood group antigens (HBGAs) are norovirus binding ligands, and antigenic and preferential HBGA binding profiles vary over time as new GII.4 strains emerge. The capsid P2 subdomain facilitates HBGA binding, contains neutralizing antibody epitopes, and likely evolves in response to herd immunity. To identify amino acids regulating HBGA binding and antigenic differences over time, we created chimeric virus-like particles (VLPs) between the GII.4-1987 and GII.4-2006 strains by exchanging amino acids in putative epitopes and characterized their antigenic and HBGA binding profiles using anti-GII.4-1987 and -2006 mouse monoclonal antibodies (MAbs) and polyclonal sera, 1988 outbreak human sera, and synthetic HBGAs. The exchange of amino acids 393 to 395 between GII.4-1987 and GII.4-2006 resulted in altered synthetic HBGA binding compared to parental strains. Introduction of GII.4-1987 residues 294, 297 to 298, 368, and 372 (epitope A) into GII.4-2006 resulted in reactivity with three anti-GII.4-1987 MAbs and reduced reactivity with four anti-GII.4-2006 MAbs. The three anti-GII.4-1987 MAbs also blocked chimeric VLP-HBGA interaction, while an anti-GII.4-2006 blocking antibody did not, indicating that epitope A amino acids comprise a potential neutralizing epitope for GII.4-1987 and GII.4-2006. We also tested GII.4-1987-immunized mouse polyclonal sera and 1988 outbreak human sera for the ability to block chimeric VLP-HBGA interaction and found that epitope A amino acids contribute significantly to the GII.4-1987 blockade response. Our data provide insights that help explain the emergence of new GII.4 epidemic strains over time, may aid development of norovirus therapeutics, and may help predict the emergence of future epidemic strains.

Citing Articles

Conformational Flexibility in Capsids Encoded by the .

Lewis C, Sherry L, Conley M, Nakashima M, Akbar S, Govindan N Viruses. 2025; 16(12.

PMID: 39772145 PMC: 11680396. DOI: 10.3390/v16121835.

In Vitro Culture of Human Norovirus in the Last 20 Years.

Cheng C, Cai X, Li J, Zhang X, Xie Y, Zhang J Biomedicines. 2024; 12(11).

PMID: 39595008 PMC: 11592199. DOI: 10.3390/biomedicines12112442.

Biological Specimen Banking as a Time Capsule to Explore the Temporal Dynamics of Norovirus Epidemiology.

Bonura F, Filizzolo C, Pizzo M, Sanfilippo G, Cacioppo F, Palazzotto E Viruses. 2023; 15(12).

PMID: 38140544 PMC: 10747129. DOI: 10.3390/v15122303.

Emergence of Novel Norovirus GII.4 Variant.

Chhabra P, Tully D, Mans J, Niendorf S, Barclay L, Cannon J Emerg Infect Dis. 2023; 30(1):163-167.

PMID: 38063078 PMC: 10756382. DOI: 10.3201/eid3001.231003.

Cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein.

Ford-Siltz L, Tohma K, Alvarado G, Kendra J, Pilewski K, Crowe Jr J Front Immunol. 2022; 13:1040836.

PMID: 36389818 PMC: 9641292. DOI: 10.3389/fimmu.2022.1040836.

References

Mattner F, Sohr D, Heim A, Gastmeier P, Vennema H, Koopmans M . Risk groups for clinical complications of norovirus infections: an outbreak investigation. Clin Microbiol Infect. 2006; 12(1):69-74. DOI: 10.1111/j.1469-0691.2005.01299.x. View

Lindesmith L, Donaldson E, Baric R . Norovirus GII.4 strain antigenic variation. J Virol. 2010; 85(1):231-42. PMC: 3014165. DOI: 10.1128/JVI.01364-10. View

El-Kamary S, Pasetti M, Mendelman P, Frey S, Bernstein D, Treanor J . Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis. 2010; 202(11):1649-58. PMC: 3722871. DOI: 10.1086/657087. View

Bush R, FITCH W, BENDER C, Cox N . Positive selection on the H3 hemagglutinin gene of human influenza virus A. Mol Biol Evol. 1999; 16(11):1457-65. DOI: 10.1093/oxfordjournals.molbev.a026057. View

Tan M, Xia M, Cao S, Huang P, Farkas T, Meller J . Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis study. Virology. 2008; 379(2):324-34. PMC: 3503251. DOI: 10.1016/j.virol.2008.06.041. View

Zolla-Pazner S . Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol. 2004; 4(3):199-210. PMC: 7097025. DOI: 10.1038/nri1307. View

Jiang X, Wang M, Graham D, Estes M . Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol. 1992; 66(11):6527-32. PMC: 240146. DOI: 10.1128/JVI.66.11.6527-6532.1992. View

Ronquist F, Huelsenbeck J . MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics. 2003; 19(12):1572-4. DOI: 10.1093/bioinformatics/btg180. View

Mead P, Slutsker L, Dietz V, McCaig L, Bresee J, Shapiro C . Food-related illness and death in the United States. Emerg Infect Dis. 1999; 5(5):607-25. PMC: 2627714. DOI: 10.3201/eid0505.990502. View

10.

Okada M, Tanaka T, Oseto M, Takeda N, Shinozaki K . Genetic analysis of noroviruses associated with fatalities in healthcare facilities. Arch Virol. 2006; 151(8):1635-41. DOI: 10.1007/s00705-006-0739-6. View

11.

Lee V, Tay J, Chen M, Phoon M, Xie M, Wu Y . Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains. Vaccine. 2010; 28(42):6852-7. DOI: 10.1016/j.vaccine.2010.08.031. View

12.

Siebenga J, Vennema H, Renckens B, de Bruin E, van der Veer B, Siezen R . Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J Virol. 2007; 81(18):9932-41. PMC: 2045401. DOI: 10.1128/JVI.00674-07. View

13.

Ferguson N, Galvani A, Bush R . Ecological and immunological determinants of influenza evolution. Nature. 2003; 422(6930):428-33. DOI: 10.1038/nature01509. View

14.

LoBue A, Lindesmith L, Baric R . Identification of cross-reactive norovirus CD4+ T cell epitopes. J Virol. 2010; 84(17):8530-8. PMC: 2919024. DOI: 10.1128/JVI.00727-10. View

15.

Shanker S, Choi J, Sankaran B, Atmar R, Estes M, Prasad B . Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J Virol. 2011; 85(17):8635-45. PMC: 3165782. DOI: 10.1128/JVI.00848-11. View

16.

Murata T, Katsushima N, Mizuta K, Muraki Y, Hongo S, Matsuzaki Y . Prolonged norovirus shedding in infants <or=6 months of age with gastroenteritis. Pediatr Infect Dis J. 2007; 26(1):46-9. DOI: 10.1097/01.inf.0000247102.04997.e0. View

17.

Patel M, Widdowson M, Glass R, Akazawa K, Vinje J, Parashar U . Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis. 2008; 14(8):1224-31. PMC: 2600393. DOI: 10.3201/eid1408.071114. View

18.

Cao S, Lou Z, Tan M, Chen Y, Liu Y, Zhang Z . Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol. 2007; 81(11):5949-57. PMC: 1900264. DOI: 10.1128/JVI.00219-07. View

19.

Yewdell J . Monoclonal antibodies specific for discontinuous epitopes direct refolding of influenza A virus hemagglutinin. Mol Immunol. 2010; 47(5):1132-6. PMC: 2814887. DOI: 10.1016/j.molimm.2009.10.023. View

20.

Atmar R, Estes M . The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am. 2006; 35(2):275-90, viii. DOI: 10.1016/j.gtc.2006.03.001. View